Literature DB >> 7970725

Reversion of Ras transformed cells by Ets transdominant mutants.

C Wasylyk1, S M Maira, P Sobieszczuk, B Wasylyk.   

Abstract

Considerable progress has been made in elucidating the components of the Ras signalling pathway, from both biochemical and genetic investigations. However little is known about the nuclear targets of the pathway, and in particular those that mediate the long-term changes in gene expression resulting from Ras transformation. Ets family members may be involved in these processes since Ras stimulates transcription through ets-DNA binding sites. We show that a mutated Ets protein, delta PU.1, inhibits Ras activation of transcription. Stable expression of delta PU.1 in Ras transformed NIH3T3 fibroblasts reverts the transformed phenotype by many characteristics, including morphology, anchorage independent growth, saturation density, growth in low serum, tumour formation in nude mice and to some extent sensitivity to apoptotic cell death. Similar trans-dominant mutants of c-Ets-1 and c-Ets-2, the most divergent members of the Ets-family to PU.1, also revert Ras transformed cells, as indicated by morphology, anchorage-independent growth, saturation density and doubling time in low serum. Reversion may result from a shared property of the mutants, such as binding to ets motifs in promoters. These results provide evidence for an important role for Ets proteins in Ras transformation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7970725

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Direct regulation of BCL-2 by FLI-1 is involved in the survival of FLI-1-transformed erythroblasts.

Authors:  Isabelle Lesault; Christine Tran Quang; Jon Frampton; Jacques Ghysdael
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

2.  Transcriptional repressor ERF is a Ras/mitogen-activated protein kinase target that regulates cellular proliferation.

Authors:  L Le Gallic; D Sgouras; G Beal; G Mavrothalassitis
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

Review 3.  ETV6 in hematopoiesis and leukemia predisposition.

Authors:  Hanno Hock; Akiko Shimamura
Journal:  Semin Hematol       Date:  2017-04-07       Impact factor: 3.851

4.  Ets transcription factors control epithelial maturation and transit and crypt-villus morphogenesis in the mammalian intestine.

Authors:  Paul Jedlicka; Xiaomei Sui; Lori Sussel; Arthur Gutierrez-Hartmann
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

5.  Pleiotropic action of AP-1 in v-Src-transformed cells.

Authors:  Lizhen Wang; Natalie A Rodrigues; Ying Wu; Bart M Maslikowski; Nishi Singh; Samantha Lacroix; Pierre-André Bédard
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

6.  Control of B cell development by Ras-mediated activation of Raf.

Authors:  B M Iritani; K A Forbush; M A Farrar; R M Perlmutter
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

7.  Net-b, a Ras-insensitive factor that forms ternary complexes with serum response factor on the serum response element of the fos promoter.

Authors:  A Giovane; P Sobieszczuk; A Ayadi; S M Maira; B Wasylyk
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

8.  Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.

Authors:  Bart M Maślikowski; Benjamin D Néel; Ying Wu; Lizhen Wang; Natalie A Rodrigues; Germain Gillet; Pierre-André Bédard
Journal:  BMC Cancer       Date:  2010-02-12       Impact factor: 4.430

9.  Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells.

Authors:  Giuseppina M Carbone; Sara Napoli; Alessandra Valentini; Franco Cavalli; Dennis K Watson; Carlo V Catapano
Journal:  Nucleic Acids Res       Date:  2004-08-16       Impact factor: 16.971

10.  Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks.

Authors:  Kouichi Tabu; Taichi Kimura; Ken Sasai; Lei Wang; Norihisa Bizen; Hiroshi Nishihara; Tetsuya Taga; Shinya Tanaka
Journal:  Mol Cancer       Date:  2010-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.